首页> 外文OA文献 >Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma
【2h】

Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma

机译:血清间皮素,骨桥蛋白和波形蛋白:用于临床监测恶性胸膜间皮瘤的有用标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Malignant pleural mesothelioma (MPM) is a relatively rare tumor, with the epithelioid type occurring more frequently. Several biomarkers have been suggested for screening and early diagnosis of MPM. Currently, high levels of soluble mesothelin-related peptides (SMRP), plasma osteopontin (pOPN) and vimentin have been reported in patients with MPM as promising markers for diagnosis, but their clinical use in monitoring is still discussed. The aim of our study was to evaluate the usefulness of these substances as markers of the clinical response to treatment in patients suffering from epithelioid mesothelioma.
机译:恶性胸膜间皮瘤(MPM)是一种相对罕见的肿瘤,上皮样类型的发生率更高。已经提出了几种生物标记物用于MPM的筛查和早期诊断。目前,已经报道了MPM患者中高水平的可溶性间皮素相关肽(SMRP),血浆骨桥蛋白(pOPN)和波形蛋白是诊断的有希望的标志物,但是仍在讨论其在监测中的临床应用。我们研究的目的是评估这些物质作为上皮样间皮瘤患者临床治疗反应指标的有用性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号